NASDAQ:FOMX - Foamix Pharmaceuticals Price Target & Analyst Ratings

Sign in or create an account to add this stock to your watchlist.
$5.46 +0.05 (+0.92 %)
(As of 07/20/2018 01:55 PM ET)
Previous Close$5.44
Today's Range$5.44 - $5.58
52-Week Range$4.34 - $7.45
Volume1,940 shs
Average Volume97,068 shs
Market Capitalization$219.94 million
P/E Ratio-3.07
Dividend YieldN/A
Beta1.9

Analyst Ratings

Foamix Pharmaceuticals (NASDAQ:FOMX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Foamix Pharmaceuticals in the last 12 months. Their average twelve-month price target is $10.00, suggesting that the stock has a possible upside of 83.15%. The high price target for FOMX is $12.00 and the low price target for FOMX is $8.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.00$9.6667$9.6667$9.6667
Price Target Upside: 83.15% upside91.04% upside77.37% upside45.58% upside

Foamix Pharmaceuticals (NASDAQ:FOMX) Consensus Price Target History

Price Target History for Foamix Pharmaceuticals (NASDAQ:FOMX)

Foamix Pharmaceuticals (NASDAQ:FOMX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/16/2018HC WainwrightReiterated RatingBuy$12.00LowView Rating Details
12/14/2017GuggenheimReiterated RatingBuy$8.00HighView Rating Details
7/19/2017Credit Suisse GroupReiterated RatingBuy$9.00LowView Rating Details
(Data available from 7/20/2016 forward)
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.